Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancers Ročník 12; číslo 6; s. 1449
Hlavní autori: Mollica, Veronica, Rizzo, Alessandro, Montironi, Rodolfo, Cheng, Liang, Giunchi, Francesca, Schiavina, Riccardo, Santoni, Matteo, Fiorentino, Michelangelo, Lopez-Beltran, Antonio, Brunocilla, Eugenio, Brandi, Giovanni, Massari, Francesco
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI 02.06.2020
Predmet:
Review
urothelial carcinoma
immunotherapy
PD-L1
antibody drug conjugates
clinical trials
immune checkpoint inhibitors
FGFR
PD-1
ISSN:2072-6694, 2072-6694
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.
AbstractList Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.
Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunotherapeutic approaches in UC therapy, where immune checkpoint inhibitors have been revolutionizing the treatment of metastatic UC. Because of a better tumor molecular profiling, FGFR inhibitors, PARP inhibitors, anti-HER2 agents, and antibody drug conjugates targeting Nectin-4 are also emerging as new therapeutic options. Moreover, a wide number of trials is ongoing with the aim to evaluate several other alterations and pathways as new potential targets in metastatic UC. In this review, we will discuss the recent advances and highlight future directions of the medical treatment of UC, with a particular focus on recently published data and ongoing active and recruiting trials.
Author Montironi, Rodolfo
Giunchi, Francesca
Santoni, Matteo
Rizzo, Alessandro
Brandi, Giovanni
Lopez-Beltran, Antonio
Cheng, Liang
Schiavina, Riccardo
Brunocilla, Eugenio
Massari, Francesco
Mollica, Veronica
Fiorentino, Michelangelo
AuthorAffiliation 2 Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy
6 Department of Urology, University of Bologna, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; riccardo.schiavina3@unibo.it (R.S.); eugenio.brunocilla@unibo.it (E.B.)
5 Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; frachikka@virgilio.it
7 Oncology Unit, Macerata Hospital, 62100 Macerata, Italy; mattymo@alice.it
9 Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, 14071 Cordoba, Spain; em1lobea@gmail.com
4 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA; liang_cheng@yahoo.com
1 Division of Oncology, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy; veronica.mollica7@gmail.com (V.M.); rizzo.alessandro179@gmail.com (A.R.); giovanni.brandi@unibo.it (G.B.)
8 Department of Pathology, University of Bologna, School of Medicine, 40126 Bologna, Ita
AuthorAffiliation_xml – name: 3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60121 Ancona, Italy; r.montironi@staff.univpm.it
– name: 2 Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy
– name: 4 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA; liang_cheng@yahoo.com
– name: 9 Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, 14071 Cordoba, Spain; em1lobea@gmail.com
– name: 7 Oncology Unit, Macerata Hospital, 62100 Macerata, Italy; mattymo@alice.it
– name: 5 Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; frachikka@virgilio.it
– name: 1 Division of Oncology, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy; veronica.mollica7@gmail.com (V.M.); rizzo.alessandro179@gmail.com (A.R.); giovanni.brandi@unibo.it (G.B.)
– name: 6 Department of Urology, University of Bologna, S-Orsola-Malpighi Hospital, 40138 Bologna, Italy; riccardo.schiavina3@unibo.it (R.S.); eugenio.brunocilla@unibo.it (E.B.)
– name: 8 Department of Pathology, University of Bologna, School of Medicine, 40126 Bologna, Italy; michelangelo.fiorentino@unibo.it
Author_xml – sequence: 1
  givenname: Veronica
  surname: Mollica
  fullname: Mollica, Veronica
– sequence: 2
  givenname: Alessandro
  orcidid: 0000-0002-5257-8678
  surname: Rizzo
  fullname: Rizzo, Alessandro
– sequence: 3
  givenname: Rodolfo
  surname: Montironi
  fullname: Montironi, Rodolfo
– sequence: 4
  givenname: Liang
  orcidid: 0000-0001-6049-5293
  surname: Cheng
  fullname: Cheng, Liang
– sequence: 5
  givenname: Francesca
  surname: Giunchi
  fullname: Giunchi, Francesca
– sequence: 6
  givenname: Riccardo
  surname: Schiavina
  fullname: Schiavina, Riccardo
– sequence: 7
  givenname: Matteo
  surname: Santoni
  fullname: Santoni, Matteo
– sequence: 8
  givenname: Michelangelo
  orcidid: 0000-0002-1749-150X
  surname: Fiorentino
  fullname: Fiorentino, Michelangelo
– sequence: 9
  givenname: Antonio
  surname: Lopez-Beltran
  fullname: Lopez-Beltran, Antonio
– sequence: 10
  givenname: Eugenio
  surname: Brunocilla
  fullname: Brunocilla, Eugenio
– sequence: 11
  givenname: Giovanni
  surname: Brandi
  fullname: Brandi, Giovanni
– sequence: 12
  givenname: Francesco
  orcidid: 0000-0001-6476-6871
  surname: Massari
  fullname: Massari, Francesco
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32498352$$D View this record in MEDLINE/PubMed
BookMark eNp1UUtLxDAQDqL43LM36dHLat5pL4IsvsDHwV08hmmaupFuU5NU8N_bRVfWBecyA_M9-GYO0HbrW4vQMcFnjBX43EBrbIiEYkk4L7bQPsWKjqUs-PbavIdGMb7hoRgjSqpdtMcoL3Im6D56mfQh2DZlzylAsq_OxgzaKnv0H7bJpnMboLN9cia77LrgwcwHQO1D9mATxATLzSz4NLeNgyabQDCu9Qs4Qjs1NNGOfvohml1fTSe34_unm7vJ5f3YcFGksZGm4ISosiBCVoaVuQBW4oqVpcK5waIyRFZMcoqFyVVOQNaVrEBxzmtJgR2ii2_dri8XtjJDlACN7oJbQPjUHpz-u2ndXL_6D62G-IWig8Dpj0Dw772NSS9cNLZpoLW-j5pygpnIheID9GTd69dkdc0BIL4BJvgYg621ccsT-aW1azTBevk4vfG4gXe-wVtJ_8f4AhBlnd8
CitedBy_id crossref_primary_10_2217_fon_2021_0841
crossref_primary_10_3390_ijms23158133
crossref_primary_10_1080_17474124_2021_1853527
crossref_primary_10_1038_s41598_023_44103_9
crossref_primary_10_1080_14712598_2023_2201371
crossref_primary_10_1016_j_critrevonc_2021_103306
crossref_primary_10_3390_jpm12050842
crossref_primary_10_1007_s00432_023_05584_3
crossref_primary_10_1016_j_prp_2021_153410
crossref_primary_10_1016_j_ctarc_2021_100337
crossref_primary_10_1016_j_ctarc_2022_100537
crossref_primary_10_1007_s00262_024_03682_w
crossref_primary_10_1080_14740338_2022_1996561
crossref_primary_10_3389_fonc_2022_866013
crossref_primary_10_1080_17425255_2022_2072727
crossref_primary_10_3390_cells9092051
crossref_primary_10_1016_j_prp_2022_153983
crossref_primary_10_1159_000534150
crossref_primary_10_3389_fonc_2021_671327
crossref_primary_10_3390_cancers13215500
crossref_primary_10_1016_j_ctarc_2021_100328
crossref_primary_10_1016_j_tranon_2021_101208
crossref_primary_10_1016_j_urolonc_2022_03_008
crossref_primary_10_1038_s41598_024_65594_0
crossref_primary_10_1159_000530710
crossref_primary_10_2147_RRU_S270495
crossref_primary_10_1016_j_clim_2022_108927
crossref_primary_10_1158_1078_0432_CCR_21_2210
crossref_primary_10_1007_s40291_023_00647_0
crossref_primary_10_3390_biomedicines11082142
crossref_primary_10_3390_cancers14133256
crossref_primary_10_1007_s00262_023_03469_5
crossref_primary_10_3390_jcm11041038
crossref_primary_10_1016_j_euf_2021_01_003
crossref_primary_10_2147_CLEP_S409791
crossref_primary_10_1016_j_intimp_2023_110723
crossref_primary_10_1016_j_tranon_2021_101154
crossref_primary_10_1186_s12885_022_10424_7
crossref_primary_10_3390_cancers14205167
crossref_primary_10_1007_s10585_025_10374_x
crossref_primary_10_3389_fonc_2021_696716
crossref_primary_10_3390_ijms22179526
crossref_primary_10_1080_14712598_2021_1929168
crossref_primary_10_2147_CMAR_S287904
crossref_primary_10_1007_s41972_023_00197_x
crossref_primary_10_3390_medicina57050458
crossref_primary_10_2217_imt_2021_0006
crossref_primary_10_2217_imt_2021_0324
crossref_primary_10_1186_s12882_024_03825_2
crossref_primary_10_3390_jcm13051305
crossref_primary_10_1007_s40487_022_00218_z
crossref_primary_10_3389_fmolb_2021_800945
crossref_primary_10_2217_imt_2020_0305
crossref_primary_10_32604_biocell_2024_054873
crossref_primary_10_1016_j_acuroe_2023_12_006
crossref_primary_10_1158_2159_8290_CD_24_0866
crossref_primary_10_1080_19475411_2025_2493656
crossref_primary_10_3389_fphar_2021_723066
crossref_primary_10_1186_s13045_021_01040_2
crossref_primary_10_1007_s12094_023_03288_1
crossref_primary_10_2217_fon_2021_0570
crossref_primary_10_1080_13543784_2021_1854724
crossref_primary_10_3390_cells13231937
crossref_primary_10_1177_15330338221090093
crossref_primary_10_3390_ijms22041551
crossref_primary_10_1007_s00262_023_03518_z
crossref_primary_10_1038_s41598_024_68872_z
crossref_primary_10_1080_14737140_2022_2038565
crossref_primary_10_1016_j_acuro_2023_10_010
crossref_primary_10_1016_j_ebiom_2024_105176
Cites_doi 10.1200/JCO.2017.35.6_suppl.349
10.1016/j.eururo.2019.03.015
10.1016/S0022-5347(05)65752-7
10.1200/JCO.2001.19.10.2638
10.1016/j.ejca.2016.06.028
10.2217/fon-2019-0097
10.1200/JCO.2020.38.6_suppl.440
10.2353/ajpath.2010.100354
10.1200/JCO.2008.20.5534
10.1200/JCO.2020.38.6_suppl.441
10.2217/fon-2017-0689
10.1200/JCO.2017.75.7740
10.1158/2326-6066.CIR-15-0274
10.1080/14728222.2018.1512588
10.1038/nature12965
10.3389/fimmu.2018.00385
10.7314/APJCP.2013.14.6.3897
10.1002/jso.24012
10.1016/S0959-8049(98)00030-6
10.1038/nrc1457
10.1038/nrc3817
10.1038/nrclinonc.2016.25
10.1200/JCO.19.01140
10.1200/JCO.19.00538
10.1093/annonc/mdv509
10.3389/fonc.2020.00114
10.1016/j.ctrv.2017.12.007
10.1038/s41379-018-0061-3
10.1053/j.seminoncol.2019.01.001
10.1016/j.eururo.2017.06.012
10.1200/JCO.2017.35.6_suppl.300
10.1016/j.ctrv.2019.04.002
10.1016/S1470-2045(10)70275-8
10.1016/j.eururo.2017.03.047
10.18632/genesandcancer.180
10.1038/cmi.2017.143
10.1200/JCO.2005.07.757
10.1517/13543784.2015.1041588
10.1158/2326-6066.CIR-13-0031-T
10.1371/journal.pone.0220101
10.1016/S1470-2045(17)30065-7
10.1200/JCO.2019.37.7_suppl.354
10.1016/S0140-6736(17)33297-X
10.18632/oncotarget.25393
10.1371/journal.pone.0038972
10.1200/JCO.2011.37.7002
10.1016/S0140-6736(17)32365-6
10.1007/s00345-018-2332-5
10.1016/j.breast.2019.02.003
10.1111/bju.12601
10.1200/JCO.2011.34.8433
10.1200/JCO.2016.34.15_suppl.4534
10.1016/j.eururo.2012.07.033
10.1200/JCO.2017.35.15_suppl.4562
10.1128/MCB.25.21.9543-9553.2005
10.1016/j.ejca.2005.08.032
10.1093/annonc/mdr023
10.1016/S1470-2045(17)30900-2
10.1038/s41591-019-0420-8
10.1093/annonc/mdz394.049
10.1080/14737140.2017.1344553
10.1200/JCO.2016.34.15_suppl.TPS4574
10.1002/cncr.24467
10.1158/2326-6066.CIR-14-0137
10.1038/12615
10.1038/s41577-018-0119-y
10.1158/2159-8290.CD-18-1495
10.1016/S0002-9440(10)64665-2
10.1016/j.ctrv.2017.05.003
10.1007/978-981-32-9717-3_3
10.1002/hon.2591
10.1200/JCO.2019.37.18_suppl.LBA4505
10.1056/NEJMoa1613683
10.1158/1078-0432.CCR-14-0257
10.1056/NEJMoa1504030
10.21037/atm.2019.06.06
10.1002/cncr.30631
10.1177/1756287219839285
10.1016/j.clgc.2012.10.001
10.1038/s41467-020-14471-1
10.1038/s41585-019-0208-0
10.1016/j.eururo.2014.11.003
10.1007/s11912-020-0879-y
10.1056/NEJMoa1817323
10.1186/s13045-019-0780-z
10.1200/JCO.2017.35.15_suppl.TPS4590
10.3322/caac.21551
10.2217/imt-2019-0115
10.1016/j.critrevonc.2019.08.005
10.1177/1758835919890285
10.1056/NEJMoa1510665
10.1200/JCO.2010.31.6067
10.1007/s11912-019-0775-5
10.1016/j.urolonc.2017.12.018
10.1200/JCO.19.02044
10.1200/JCO.2018.36.15_suppl.TPS4589
10.1016/j.cell.2017.09.007
10.1007/s40261-019-00773-w
10.1371/journal.pone.0057284
10.1016/S0140-6736(16)32455-2
10.1093/annonc/mdz249
10.1016/j.critrevonc.2018.07.004
10.1016/S0140-6736(16)00561-4
10.1200/JCO.2009.26.9589
10.1093/annonc/mdz192
10.1084/jem.20071341
10.1158/1078-0432.CCR-16-2520
10.1007/978-981-32-9717-3_7
10.1111/imr.12520
10.1097/CAD.0000000000000405
10.1200/JCO.2020.38.15_suppl.5027
10.1093/annonc/mdr156
10.1016/j.bmc.2017.10.021
10.1016/S1470-2045(19)30668-0
10.1093/jnci/87.21.1603
10.1177/1078155218805141
10.1016/j.eururo.2019.09.006
10.1016/S1470-2045(12)70294-2
10.1200/JCO.2002.20.4.937
10.1111/j.1464-410X.1994.tb07122.x
10.1016/j.eururo.2016.06.010
10.1016/S1470-2045(17)30616-2
10.1158/1078-0432.CCR-14-3212
10.1200/JCO.2019.37.15_suppl.4503
10.1093/annonc/mdy424.038
10.1016/S0140-6736(17)33298-1
10.1186/s13046-019-1089-z
10.1200/JCO.2018.36.15_suppl.TPS4588
10.1200/JCO.2011.37.3571
10.1016/j.clgc.2013.11.016
10.1186/s13045-017-0423-1
10.1093/annonc/mdz249.001
ContentType Journal Article
Copyright 2020 by the authors. 2020
Copyright_xml – notice: 2020 by the authors. 2020
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.3390/cancers12061449
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC7352972
32498352
10_3390_cancers12061449
Genre Journal Article
Review
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
RPM
TUS
NPM
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c459t-c6c94117b9156dc3b85a3b0d3bb708c05dc16d364205c8781a6fd6da7444f62a3
ISICitedReferencesCount 80
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000549291000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2072-6694
IngestDate Tue Nov 04 02:04:50 EST 2025
Fri Sep 05 10:09:06 EDT 2025
Mon Jul 21 06:02:18 EDT 2025
Sat Nov 29 07:18:09 EST 2025
Tue Nov 18 21:06:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords urothelial carcinoma
immunotherapy
PD-L1
antibody drug conjugates
clinical trials
immune checkpoint inhibitors
FGFR
PD-1
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c459t-c6c94117b9156dc3b85a3b0d3bb708c05dc16d364205c8781a6fd6da7444f62a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contribution is equally to this work.
ORCID 0000-0002-1749-150X
0000-0001-6049-5293
0000-0001-6476-6871
0000-0002-5257-8678
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7352972
PMID 32498352
PQID 2410358574
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7352972
proquest_miscellaneous_2410358574
pubmed_primary_32498352
crossref_citationtrail_10_3390_cancers12061449
crossref_primary_10_3390_cancers12061449
PublicationCentury 2000
PublicationDate 20200602
PublicationDateYYYYMMDD 2020-06-02
PublicationDate_xml – month: 6
  year: 2020
  text: 20200602
  day: 2
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2020
Publisher MDPI
Publisher_xml – name: MDPI
References Tagawa (ref_82) 2019; 30
Redmond (ref_112) 2014; 2
Rimar (ref_135) 2017; 123
Petrylak (ref_74) 2020; 21
Fujio (ref_117) 2017; 410
Larkin (ref_89) 2015; 373
Brown (ref_127) 2019; 19
Godwin (ref_11) 2018; 36
Antoni (ref_3) 2017; 71
Galsky (ref_85) 2018; 36
Bellmunt (ref_33) 2009; 27
Powles (ref_84) 2017; 35
Rosenberg (ref_76) 2020; 38
Balar (ref_28) 2017; 18
Lichtenegger (ref_116) 2018; 9
Fong (ref_134) 2010; 28
Sharma (ref_90) 2019; 37
Sermer (ref_125) 2019; 37
Cappellen (ref_54) 1999; 23
Bernardini (ref_64) 2001; 166
Criscuolo (ref_136) 2019; 38
Teo (ref_140) 2018; 36
Piconese (ref_111) 2008; 205
Ciccarese (ref_19) 2019; 46
Mollica (ref_87) 2019; 39
Sweis (ref_57) 2016; 4
Aldous (ref_128) 2018; 26
Riccardi (ref_124) 2018; 22
Rosenberg (ref_38) 2016; 7
Galsky (ref_92) 2018; 36
Wing (ref_108) 2019; 1189
Buttigliero (ref_21) 2018; 129
Petrylak (ref_77) 2019; 37
Bellmunt (ref_24) 2012; 30
Siegel (ref_1) 2019; 69
Mazzola (ref_60) 2015; 24
Qin (ref_86) 2019; 15
Criscitiello (ref_129) 2019; 44
Turner (ref_130) 2004; 4
Tomlinson (ref_56) 2010; 177
Galsky (ref_94) 2019; 37
Kashima (ref_110) 2020; 25
Teo (ref_133) 2017; 23
Hahn (ref_71) 2011; 29
Billerey (ref_50) 2001; 158
Lurkin (ref_51) 2001; 61
Hassel (ref_88) 2017; 57
Khalil (ref_103) 2016; 13
Aldebasi (ref_61) 2013; 6
Kamoun (ref_47) 2020; 77
Tagawa (ref_81) 2019; 37
Vaughn (ref_34) 2002; 20
Petrylak (ref_73) 2017; 390
Rosenberg (ref_72) 2019; 37
Bentebibel (ref_113) 2019; 9
Casadei (ref_58) 2019; 11
Abdelaziz (ref_98) 2017; 17
Burger (ref_4) 2013; 63
Rouanne (ref_12) 2018; 36
Powles (ref_39) 2018; 391
Necchi (ref_67) 2012; 13
Messina (ref_44) 2016; 27
Galsky (ref_8) 2011; 29
Galsky (ref_7) 2012; 23
Dickinson (ref_62) 1994; 74
Pierantoni (ref_36) 2019; 143
Hoimes (ref_78) 2019; 30
Grivas (ref_138) 2020; 38
Petrylak (ref_83) 2020; 38
Lugowska (ref_142) 2019; 30
Sonpavde (ref_23) 2014; 12
Yap (ref_132) 2014; 20
So (ref_109) 2019; 1189
Galsky (ref_70) 2013; 11
Robertson (ref_46) 2017; 171
Rosenberg (ref_80) 2020; 38
ref_53
ref_52
Nadal (ref_30) 2019; 76
Sternberg (ref_26) 2001; 19
Alifrangis (ref_48) 2019; 16
Petrylak (ref_96) 2017; 35
Balar (ref_29) 2017; 7
Hanna (ref_13) 2019; 25
Apolo (ref_68) 2016; 34
Crist (ref_43) 2019; 11
Powles (ref_17) 2017; 72
Piao (ref_119) 2013; 14
Dreicer (ref_65) 2009; 115
Massari (ref_99) 2019; 7
Sternberg (ref_102) 2019; 76
Necchi (ref_5) 2016; 15
Patel (ref_41) 2018; 19
Knowles (ref_49) 2015; 15
Loriot (ref_59) 2019; 381
Zhou (ref_120) 2015; 8
Helsten (ref_55) 2016; 22
Galsky (ref_139) 2017; 35
Sharma (ref_40) 2017; 18
Massari (ref_18) 2018; 391
Powles (ref_93) 2016; 34
Rosenberg (ref_91) 2018; 29
Apolo (ref_100) 2017; 35
Dill (ref_107) 2018; 31
Yang (ref_121) 2015; 112
Massari (ref_16) 2019; 11
Theate (ref_105) 2015; 3
Motzer (ref_15) 2015; 373
Parry (ref_14) 2005; 25
Wang (ref_126) 2017; 10
Bellmunt (ref_37) 2017; 16
Zhai (ref_104) 2018; 15
Rijnders (ref_20) 2017; 72
Sengelov (ref_25) 2005; 23
Geldart (ref_95) 2015; 67
Smith (ref_2) 2014; 114
Meireson (ref_106) 2018; 9
Das (ref_118) 2017; 276
Raggi (ref_9) 2016; 27
Baxter (ref_97) 2018; 14
Long (ref_115) 2018; 9
Zappasodi (ref_123) 2019; 25
Garje (ref_137) 2020; 10
Bellmunt (ref_66) 2011; 22
Sternberg (ref_6) 2006; 42
Lattanzi (ref_10) 2019; 21
Powles (ref_42) 2017; 14
Mateo (ref_131) 2019; 30
Powles (ref_141) 2019; 30
Sarfaty (ref_75) 2020; 22
ref_45
Galsky (ref_22) 2011; 12
ref_101
Sharma (ref_114) 2020; 11
Knee (ref_122) 2016; 67
Massari (ref_27) 2018; 64
Bochner (ref_63) 1995; 87
Redman (ref_35) 2020; 27
Rosenberg (ref_79) 2019; 37
Zarrabi (ref_31) 2019; 12
Lorusso (ref_32) 1998; 34
Choueiri (ref_69) 2012; 30
References_xml – volume: 35
  start-page: e349
  year: 2017
  ident: ref_96
  article-title: A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.6_suppl.349
– volume: 76
  start-page: 73
  year: 2019
  ident: ref_102
  article-title: Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2019.03.015
– volume: 166
  start-page: 1275
  year: 2001
  ident: ref_64
  article-title: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer
  publication-title: J. Urol.
  doi: 10.1016/S0022-5347(05)65752-7
– volume: 19
  start-page: 2638
  year: 2001
  ident: ref_26
  article-title: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2001.19.10.2638
– volume: 67
  start-page: 1
  year: 2016
  ident: ref_122
  article-title: Rationale for anti-GITR cancer immunotherapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2016.06.028
– volume: 15
  start-page: 1811
  year: 2019
  ident: ref_86
  article-title: RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
  publication-title: Future Oncol.
  doi: 10.2217/fon-2019-0097
– volume: 38
  start-page: 440
  year: 2020
  ident: ref_138
  article-title: Rucaparib for recurrent, locally advanced or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase 2 open-label trial
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.6_suppl.440
– volume: 177
  start-page: 2379
  year: 2010
  ident: ref_56
  article-title: Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer
  publication-title: Am. J. Pathol.
  doi: 10.2353/ajpath.2010.100354
– volume: 27
  start-page: 4454
  year: 2009
  ident: ref_33
  article-title: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.20.5534
– volume: 38
  start-page: 441
  year: 2020
  ident: ref_80
  article-title: Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.6_suppl.441
– volume: 14
  start-page: 2021
  year: 2018
  ident: ref_97
  article-title: Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma
  publication-title: Future Oncol.
  doi: 10.2217/fon-2017-0689
– volume: 36
  start-page: 1685
  year: 2018
  ident: ref_140
  article-title: Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.75.7740
– volume: 4
  start-page: 563
  year: 2016
  ident: ref_57
  article-title: Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-15-0274
– volume: 6
  start-page: 239
  year: 2013
  ident: ref_61
  article-title: The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy
  publication-title: Int. J. Clin. Exp. Med.
– volume: 22
  start-page: 783
  year: 2018
  ident: ref_124
  article-title: Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy
  publication-title: Expert Opin. Ther. Targets.
  doi: 10.1080/14728222.2018.1512588
– ident: ref_45
  doi: 10.1038/nature12965
– volume: 37
  start-page: e15
  year: 2019
  ident: ref_94
  article-title: A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC)
  publication-title: J. Clin. Oncol.
– volume: 9
  start-page: 385
  year: 2018
  ident: ref_116
  article-title: Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00385
– volume: 14
  start-page: 3897
  year: 2013
  ident: ref_119
  article-title: Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer
  publication-title: Asian Pac. J. Cancer Prev.
  doi: 10.7314/APJCP.2013.14.6.3897
– volume: 112
  start-page: 430
  year: 2015
  ident: ref_121
  article-title: T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.24012
– volume: 25
  start-page: 1
  year: 2020
  ident: ref_110
  article-title: High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma
  publication-title: Oncology
– volume: 34
  start-page: 1208
  year: 1998
  ident: ref_32
  article-title: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/S0959-8049(98)00030-6
– volume: 4
  start-page: 814
  year: 2004
  ident: ref_130
  article-title: Hallmarks of ‘BRCAness’ in sporadic cancers
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1457
– volume: 15
  start-page: 25
  year: 2015
  ident: ref_49
  article-title: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3817
– volume: 13
  start-page: 273
  year: 2016
  ident: ref_103
  article-title: The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2016.25
– volume: 37
  start-page: 2592
  year: 2019
  ident: ref_79
  article-title: Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.01140
– volume: 37
  start-page: 1608
  year: 2019
  ident: ref_90
  article-title: Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
  publication-title: J Clin. Oncol.
  doi: 10.1200/JCO.19.00538
– volume: 27
  start-page: 49
  year: 2016
  ident: ref_9
  article-title: Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: A systematic review and meta-analysis
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv509
– volume: 10
  start-page: 114
  year: 2020
  ident: ref_137
  article-title: PARP Inhibitors in Prostate and Urothelial Cancers
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00114
– volume: 64
  start-page: 11
  year: 2018
  ident: ref_27
  article-title: Immune checkpoint inhibitors for metastatic bladder cancer
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2017.12.007
– volume: 31
  start-page: 1513
  year: 2018
  ident: ref_107
  article-title: IDO expression in breast cancer: An assessment of 281 primary and metastatic cases with comparison to PD-L1
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-018-0061-3
– volume: 46
  start-page: 65
  year: 2019
  ident: ref_19
  article-title: Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2019.01.001
– volume: 72
  start-page: 411
  year: 2017
  ident: ref_20
  article-title: Systematic review of immune checkpoint inhibition in urological cancers
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2017.06.012
– volume: 35
  start-page: 300
  year: 2017
  ident: ref_139
  article-title: DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.6_suppl.300
– volume: 76
  start-page: 10
  year: 2019
  ident: ref_30
  article-title: Management of metastatic bladder cancer
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2019.04.002
– volume: 12
  start-page: 211
  year: 2011
  ident: ref_22
  article-title: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(10)70275-8
– volume: 72
  start-page: 477
  year: 2017
  ident: ref_17
  article-title: Immune checkpoint inhibition in metastatic urothelial cancer
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2017.03.047
– volume: 9
  start-page: 176
  year: 2018
  ident: ref_115
  article-title: The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy
  publication-title: Genes Cancer
  doi: 10.18632/genesandcancer.180
– volume: 15
  start-page: 447
  year: 2018
  ident: ref_104
  article-title: IDO1 in cancer: A Gemini of immune checkpoints
  publication-title: Cell Mol. Immunol.
  doi: 10.1038/cmi.2017.143
– volume: 23
  start-page: 4602
  year: 2005
  ident: ref_25
  article-title: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2005.07.757
– volume: 24
  start-page: 913
  year: 2015
  ident: ref_60
  article-title: Targeting the VEGF pathway in metastatic bladder cancer
  publication-title: Expert Opin. Investig. Drugs
  doi: 10.1517/13543784.2015.1041588
– volume: 2
  start-page: 142
  year: 2014
  ident: ref_112
  article-title: Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-13-0031-T
– volume: 30
  start-page: v356
  year: 2019
  ident: ref_142
  article-title: Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
  publication-title: Ann. Oncol.
– ident: ref_101
  doi: 10.1371/journal.pone.0220101
– volume: 18
  start-page: 312
  year: 2017
  ident: ref_40
  article-title: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30065-7
– volume: 37
  start-page: 2019
  year: 2019
  ident: ref_81
  article-title: Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.7_suppl.354
– volume: 391
  start-page: 748
  year: 2018
  ident: ref_39
  article-title: Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)33297-X
– volume: 9
  start-page: 25216
  year: 2018
  ident: ref_106
  article-title: Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25393
– ident: ref_52
  doi: 10.1371/journal.pone.0038972
– volume: 30
  start-page: 507
  year: 2012
  ident: ref_69
  article-title: Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.37.7002
– volume: 390
  start-page: 2266
  year: 2017
  ident: ref_73
  article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): A randomised, double-blind, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)32365-6
– volume: 36
  start-page: 1727
  year: 2018
  ident: ref_12
  article-title: Development of immunotherapy in bladder cancer: Present and future on targeting PD(L)1 and CTLA-4 pathways
  publication-title: World J. Urol.
  doi: 10.1007/s00345-018-2332-5
– volume: 44
  start-page: 128
  year: 2019
  ident: ref_129
  article-title: Peptide vaccines in early breast cancer
  publication-title: Breast
  doi: 10.1016/j.breast.2019.02.003
– volume: 114
  start-page: 719
  year: 2014
  ident: ref_2
  article-title: Muscle-invasive bladder cancer: Evaluating treatment and survival in the National Cancer Data Base
  publication-title: BJU Int.
  doi: 10.1111/bju.12601
– volume: 29
  start-page: 2432
  year: 2011
  ident: ref_8
  article-title: Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.34.8433
– volume: 34
  start-page: abstr 4534
  year: 2016
  ident: ref_68
  article-title: A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.34.15_suppl.4534
– volume: 63
  start-page: 234
  year: 2013
  ident: ref_4
  article-title: Epidemiology and risk factors of urothelial bladder cancer
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2012.07.033
– volume: 35
  start-page: e4562
  year: 2017
  ident: ref_100
  article-title: A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.4562
– volume: 25
  start-page: 9543
  year: 2005
  ident: ref_14
  article-title: CTLA- 4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.25.21.9543-9553.2005
– volume: 42
  start-page: 50
  year: 2006
  ident: ref_6
  article-title: Seven years update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2005.08.032
– volume: 14
  start-page: 3
  year: 2017
  ident: ref_42
  article-title: Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study
  publication-title: JAMA Oncol.
– volume: 22
  start-page: 2646
  year: 2011
  ident: ref_66
  article-title: Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdr023
– volume: 8
  start-page: 8018
  year: 2015
  ident: ref_120
  article-title: Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 19
  start-page: 51
  year: 2018
  ident: ref_41
  article-title: Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30900-2
– volume: 15
  start-page: 331
  year: 2016
  ident: ref_5
  article-title: Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first- line setting of metastatic urothelial carcinoma: A systematic review and meta- analysis
  publication-title: Clin. Genitourin. Cancer
– volume: 25
  start-page: 759
  year: 2019
  ident: ref_123
  article-title: Rational design of anti-GITR-based combination immunotherapy
  publication-title: Nat. Med.
  doi: 10.1038/s41591-019-0420-8
– volume: 30
  start-page: v851
  year: 2019
  ident: ref_82
  article-title: Initial Results From Trophy-U-01: A Phase 2 Open-Label Study Of Sacituzumab Govitecan In Patients (Pts) With Metastatic Urothelial Cancer (Muc) After Failure Of Platinum-Based Regimens (Plt) Or Immunotherapy
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz394.049
– volume: 17
  start-page: 577
  year: 2017
  ident: ref_98
  article-title: Cabozantinib for the treatment of kidney cancer
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1080/14737140.2017.1344553
– volume: 34
  start-page: TPS4574
  year: 2016
  ident: ref_93
  article-title: A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy(CT) in patients (pts) with unresectable stage IV urothelial bladder cancer (UBC): DANUBE
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.34.15_suppl.TPS4574
– volume: 115
  start-page: 4090
  year: 2009
  ident: ref_65
  article-title: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: A trial of the Eastern Cooperative Oncology Group
  publication-title: Cancer
  doi: 10.1002/cncr.24467
– volume: 3
  start-page: 161
  year: 2015
  ident: ref_105
  article-title: Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0137
– volume: 23
  start-page: 18
  year: 1999
  ident: ref_54
  article-title: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
  publication-title: Nat. Genet.
  doi: 10.1038/12615
– volume: 19
  start-page: 73
  year: 2019
  ident: ref_127
  article-title: CAR T cell therapy: Inroads to response and resistance
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-018-0119-y
– volume: 9
  start-page: 711
  year: 2019
  ident: ref_113
  article-title: A first-in-human study and biomarker analysis of NKTR-214, a novel IL-2-receptor beta/gamma (betagamma)-biased cytokine, in patients with advanced or metastatic solid tumors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1495
– volume: 410
  start-page: 29
  year: 2017
  ident: ref_117
  article-title: Overview of LAG-3-Expressing, IL-10-Producing Regulatory T Cells
  publication-title: Curr. Top. Microbiol. Immunol.
– volume: 158
  start-page: 1955
  year: 2001
  ident: ref_50
  article-title: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
  publication-title: Am. J. Pathol.
  doi: 10.1016/S0002-9440(10)64665-2
– volume: 57
  start-page: 36
  year: 2017
  ident: ref_88
  article-title: Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2017.05.003
– volume: 1189
  start-page: 53
  year: 2019
  ident: ref_109
  article-title: The TNF-TNFR Family of Co-signal Molecules
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-32-9717-3_3
– volume: 37
  start-page: 95
  year: 2019
  ident: ref_125
  article-title: CAR T-cell therapy: Full speed ahead
  publication-title: Hematol. Oncol.
  doi: 10.1002/hon.2591
– volume: 37
  start-page: 4505
  year: 2019
  ident: ref_77
  article-title: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.18_suppl.LBA4505
– volume: 16
  start-page: 1015
  year: 2017
  ident: ref_37
  article-title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1613683
– volume: 20
  start-page: 6605
  year: 2014
  ident: ref_132
  article-title: Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-0257
– volume: 373
  start-page: 23
  year: 2015
  ident: ref_89
  article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1504030
– volume: 7
  start-page: S137
  year: 2019
  ident: ref_99
  article-title: Another one in the chamber: Cabozantinib for patients with metastatic non clear cell renal cell carcinoma
  publication-title: Ann. Transl. Med.
  doi: 10.21037/atm.2019.06.06
– volume: 123
  start-page: 1912
  year: 2017
  ident: ref_135
  article-title: The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies
  publication-title: Cancer
  doi: 10.1002/cncr.30631
– volume: 11
  start-page: 1756287219839285
  year: 2019
  ident: ref_43
  article-title: Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: Clinical trial evidence and experience
  publication-title: Ther. Adv. Urol.
  doi: 10.1177/1756287219839285
– volume: 11
  start-page: 175
  year: 2013
  ident: ref_70
  article-title: Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer
  publication-title: Clin. Genitourin. Cancer
  doi: 10.1016/j.clgc.2012.10.001
– volume: 11
  start-page: 661
  year: 2020
  ident: ref_114
  article-title: Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-14471-1
– volume: 16
  start-page: 465
  year: 2019
  ident: ref_48
  article-title: Molecular and histopathology directed therapy for advanced bladder cancer
  publication-title: Nat. Rev. Urol.
  doi: 10.1038/s41585-019-0208-0
– volume: 67
  start-page: 599
  year: 2015
  ident: ref_95
  article-title: SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2014.11.003
– volume: 22
  start-page: 13
  year: 2020
  ident: ref_75
  article-title: Antibody-Drug Conjugates in Urothelial Carcinomas
  publication-title: Curr. Oncol. Rep.
  doi: 10.1007/s11912-020-0879-y
– volume: 381
  start-page: 338
  year: 2019
  ident: ref_59
  article-title: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1817323
– volume: 61
  start-page: 1265
  year: 2001
  ident: ref_51
  article-title: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate
  publication-title: Cancer Res.
– volume: 12
  start-page: 89
  year: 2019
  ident: ref_31
  article-title: Emerging therapeutic agents for genitourinary cancers
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-019-0780-z
– volume: 35
  start-page: e15
  year: 2017
  ident: ref_84
  article-title: Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.TPS4590
– volume: 69
  start-page: 7
  year: 2019
  ident: ref_1
  article-title: Cancer statistics, 2019
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21551
– volume: 11
  start-page: 1507
  year: 2019
  ident: ref_16
  article-title: Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice
  publication-title: Immunotherapy
  doi: 10.2217/imt-2019-0115
– volume: 143
  start-page: 46
  year: 2019
  ident: ref_36
  article-title: Immunotherapy and urothelial carcinoma: An overview and future perspectives
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2019.08.005
– volume: 11
  start-page: 1758835919890285
  year: 2019
  ident: ref_58
  article-title: Targeted therapies for advanced bladder cancer: New strategies with FGFR inhibitors
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758835919890285
– volume: 373
  start-page: 1803e13
  year: 2015
  ident: ref_15
  article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1510665
– volume: 29
  start-page: 1525
  year: 2011
  ident: ref_71
  article-title: Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.31.6067
– volume: 21
  start-page: 24
  year: 2019
  ident: ref_10
  article-title: Current status and future direction of immunotherapy in urothelial carcinoma
  publication-title: Curr. Oncol. Rep.
  doi: 10.1007/s11912-019-0775-5
– volume: 36
  start-page: 109
  year: 2018
  ident: ref_11
  article-title: Recent developments in the treatment of advanced bladder cancer
  publication-title: Urol. Oncol.
  doi: 10.1016/j.urolonc.2017.12.018
– volume: 38
  start-page: 1041
  year: 2020
  ident: ref_76
  article-title: EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.19.02044
– volume: 36
  start-page: e15
  year: 2018
  ident: ref_85
  article-title: IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.36.15_suppl.TPS4589
– volume: 171
  start-page: 540
  year: 2017
  ident: ref_46
  article-title: Comprehensive molecular characterization of muscle-invasive bladder cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.007
– volume: 39
  start-page: 503
  year: 2019
  ident: ref_87
  article-title: Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
  publication-title: Clin. Drug Investig.
  doi: 10.1007/s40261-019-00773-w
– ident: ref_53
  doi: 10.1371/journal.pone.0057284
– volume: 7
  start-page: 67
  year: 2017
  ident: ref_29
  article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32455-2
– volume: 30
  start-page: v356
  year: 2019
  ident: ref_78
  article-title: EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz249
– volume: 27
  start-page: 1
  year: 2020
  ident: ref_35
  article-title: Novel immunotherapy combinations for genitourinary cancers
  publication-title: Expert Opin. Biol. Ther.
– volume: 129
  start-page: 124
  year: 2018
  ident: ref_21
  article-title: Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2018.07.004
– volume: 7
  start-page: 1909
  year: 2016
  ident: ref_38
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00561-4
– volume: 28
  start-page: 2512
  year: 2010
  ident: ref_134
  article-title: Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2009.26.9589
– volume: 30
  start-page: 1437
  year: 2019
  ident: ref_131
  article-title: A decade of clinical development of PARP inhibitors in perspective
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz192
– volume: 205
  start-page: 825
  year: 2008
  ident: ref_111
  article-title: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20071341
– volume: 23
  start-page: 3610
  year: 2017
  ident: ref_133
  article-title: DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2520
– volume: 1189
  start-page: 179
  year: 2019
  ident: ref_108
  article-title: Control of Regulatory T Cells by Co-signal Molecules
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-32-9717-3_7
– volume: 276
  start-page: 97
  year: 2017
  ident: ref_118
  article-title: Tim-3 and its role in regulating antitumor immunity
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12520
– volume: 27
  start-page: 917
  year: 2016
  ident: ref_44
  article-title: Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0000000000000405
– volume: 38
  start-page: 5027
  year: 2020
  ident: ref_83
  article-title: Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.15_suppl.5027
– volume: 23
  start-page: 406
  year: 2012
  ident: ref_7
  article-title: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdr156
– volume: 26
  start-page: 2842
  year: 2018
  ident: ref_128
  article-title: Personalized neoantigen vaccines: A new approach to cancer immunotherapy
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2017.10.021
– volume: 21
  start-page: 105
  year: 2020
  ident: ref_74
  article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): Overall survival and updated results of a randomised, double-blind, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30668-0
– volume: 87
  start-page: 1603
  year: 1995
  ident: ref_63
  article-title: Angiogenesis in bladder cancer: Relationship between microvessel density and tumour prognosis
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/87.21.1603
– volume: 25
  start-page: 648
  year: 2019
  ident: ref_13
  article-title: Updates and novel treatments in urothelial carcinoma
  publication-title: J. Oncol. Pharm. Pract.
  doi: 10.1177/1078155218805141
– volume: 77
  start-page: 420
  year: 2020
  ident: ref_47
  article-title: A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2019.09.006
– volume: 13
  start-page: 810
  year: 2012
  ident: ref_67
  article-title: Pazopanib in advanced and platinum-resistant urothelial cancer: An open-label, single group, phase 2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(12)70294-2
– volume: 20
  start-page: 937
  year: 2002
  ident: ref_34
  article-title: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2002.20.4.937
– volume: 74
  start-page: 762
  year: 1994
  ident: ref_62
  article-title: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
  publication-title: Br. J. Urol.
  doi: 10.1111/j.1464-410X.1994.tb07122.x
– volume: 71
  start-page: 96
  year: 2017
  ident: ref_3
  article-title: Bladder cancer incidence and mortality: A global overview and recent trends
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2016.06.010
– volume: 18
  start-page: 1483
  year: 2017
  ident: ref_28
  article-title: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30616-2
– volume: 22
  start-page: 259
  year: 2016
  ident: ref_55
  article-title: The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-3212
– volume: 37
  start-page: 4503
  year: 2019
  ident: ref_72
  article-title: CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.4503
– volume: 29
  start-page: e32
  year: 2018
  ident: ref_91
  article-title: Nivolumab(N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy424.038
– volume: 391
  start-page: 716
  year: 2018
  ident: ref_18
  article-title: Atezolizumab for platinum-treated metastatic urothelial carcinoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)33298-1
– volume: 38
  start-page: 91
  year: 2019
  ident: ref_136
  article-title: New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1089-z
– volume: 36
  start-page: TPS4588
  year: 2018
  ident: ref_92
  article-title: A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs. SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC.; CheckMate 901)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2018.36.15_suppl.TPS4588
– volume: 30
  start-page: 191
  year: 2012
  ident: ref_24
  article-title: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.37.3571
– volume: 12
  start-page: 71
  year: 2014
  ident: ref_23
  article-title: Cisplatin-ineligible and chemotherapy- ineligible patients should be the focus of new drug development in patients with advanced bladder cancer
  publication-title: Clin. Genitourin. Cancer
  doi: 10.1016/j.clgc.2013.11.016
– volume: 10
  start-page: 53
  year: 2017
  ident: ref_126
  article-title: New development in CAR-T cell therapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-017-0423-1
– volume: 30
  start-page: v356
  year: 2019
  ident: ref_141
  article-title: An Adaptive, Biomarker Directed Platform Study In Metastatic Urothelial Cancer (Biscay) With Durvalumab In Combination With Targeted Therapies
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz249.001
SSID ssj0000331767
Score 2.491364
SecondaryResourceType review_article
Snippet Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1449
SubjectTerms Review
Title Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/32498352
https://www.proquest.com/docview/2410358574
https://pubmed.ncbi.nlm.nih.gov/PMC7352972
Volume 12
WOSCitedRecordID wos000549291000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M~E
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M7P
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 2072-6694
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000331767
  issn: 2072-6694
  databaseCode: M2O
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9owELcoTNNepn2PfSBPmqZJU7okduL4cUNUmwQUVXRjT5HjmBUJBQYUVf3rd-d8Aeuk7mEvVrDjmPh-HHe273eEvAUb3JdJGDiJkcLhPJVOlKDPw7lgnoHSWHb9vhgOo8lEjhqNaRkLs52LLIuuruTyv4oa6kDYGDr7D-KuHgoVcA1ChxLEDuWtBF8yLpW8syZnYR4utsaG4pfhVmiA2nAqYykZPgzMRmF4EbScrzAua46L6V3MNZQtCu1dUxpoU28DDZDYW1sr9JuxXLuVrj-bXV-XgTTrtUJ2hLpXtsEYu1l-wDtdzKdVW_fC5DqoD-j9ubsy4bv2BNXOYqXvCt8JwzyJ8bG5oa7UwP4O0sKbFDtjEk9C6vz1PN_6sbL-Dyv37Yen8cl5vx-Pe5Pxu-UvB7OL4S58kWrliLR8EcioSVqjr4PRj2o1zmVgR9l0w9UXzHmgcOCPB8PumzB_-CWHx2t37JXxA3K_cDTopxwgD0nDZI_I3UFxlOIx-V7ghNY4oSAfanFCd3BCa5xQwAmtcUJrnNAKJ0_I-Ulv3P3iFFk2HM0DuXF0qCX3PJFIcOVTzZIoUCxxU5Ykwo20G6TaC1MGfqob6EhEngqnaZgqwTmfhr5iT0kzW2TmOaGCMVdy3MhXjEN_qY0KEuZpNmVK8aRNjsuJi3VBQY-ZUOYxuKI40_HBTLfJ-6rDMmdf-futb0pJxKAhcdtLZWZxuY7BRnUZeMWCt8mzXDLVw8CdkOiDtInYk1l1A7Kv77dkswvLwi6gmxT-i1uM-5Lcq38fr0hzs7o0r8kdvd3M1qsOORKTqENan3vD0Rl8GvinWIpRp0Dpb2x8rbY
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+Strategies+and+Novel+Therapeutic+Approaches+for+Metastatic+Urothelial+Carcinoma&rft.jtitle=Cancers&rft.au=Mollica%2C+Veronica&rft.au=Rizzo%2C+Alessandro&rft.au=Montironi%2C+Rodolfo&rft.au=Cheng%2C+Liang&rft.date=2020-06-02&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=12&rft.issue=6&rft_id=info:doi/10.3390%2Fcancers12061449&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon